nach oben

PharmacoEconomics

Erschienen in:

01.07.2005 | Correspondence

The authors’ reply

verfasst von: Andrew Moore, Ceri Phillips, Elke Hunsche, James Pellissier, Simone Crespi

Erschienen in: PharmacoEconomics | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Excerpt

We would like to thank Dr Carracedo-Martínez for his interest in our paper and for his comments, and we appreciate the opportunity to respond. …

Moore A, Phillips C, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis in the UK. Pharmacoeconomics 2004; 22 (10): 643–60PubMedCrossRef

Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18 Suppl. 28: 6–10

National Institute for Clinical Excellence. Guidance on the use Gasof cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisals Process Series No 27. London, England: NICE 2001 June Report No.: N0016

Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002; 16 (4): 231–40PubMed

Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49 (3): 283–92PubMedCrossRef

Titel: The authors’ reply
verfasst von: Andrew Moore
Ceri Phillips
Elke Hunsche
James Pellissier
Simone Crespi
Publikationsdatum: 01.07.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 7/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523070-00009

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2005

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease

Price differentiation and transparency in the global pharmaceutical marketplace

Evaluating health-related quality-of-life studies in paediatric populations

The state of patient-reported outcomes in atrial fibrillation

Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information?

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma